Opus Genetics, Inc. financial data

Symbol
IRD on Nasdaq
Location
8 Davis Drive, Suite 220, Durham, NC
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 264 % -76.9%
Debt-to-equity 98.8 % +930%
Return On Equity -367 % -1115%
Return On Assets -142 % -416%
Operating Margin -421 % -359%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.9M shares +129%
Common Stock, Shares, Outstanding 59.9M shares +131%
Entity Public Float 38.7M USD -56.6%
Common Stock, Value, Issued 6K USD +100%
Weighted Average Number of Shares Outstanding, Basic 63.4M shares +145%
Weighted Average Number of Shares Outstanding, Diluted 63.4M shares +145%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 15.4M USD -6.25%
General and Administrative Expense 22.3M USD +67%
Operating Income (Loss) -64.9M USD -330%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -58.3M USD -314%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -58.3M USD -313%
Earnings Per Share, Basic -1 USD/shares -262%
Earnings Per Share, Diluted -1 USD/shares -262%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.4M USD -21.7%
Accounts Receivable, after Allowance for Credit Loss, Current 3.4M USD +150%
Other Assets, Current 86K USD +68.6%
Assets, Current 38.4M USD -14.3%
Property, Plant and Equipment, Net 226K USD
Assets 38.7M USD -13.8%
Accounts Payable, Current 1.47M USD +131%
Employee-related Liabilities, Current 1.33M USD +211%
Accrued Liabilities, Current 8.15M USD +349%
Liabilities, Current 20.2M USD +381%
Liabilities 21.2M USD +405%
Retained Earnings (Accumulated Deficit) -155M USD -60.5%
Stockholders' Equity Attributable to Parent 17.5M USD -57%
Liabilities and Equity 38.7M USD -13.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.99M USD -57.3%
Net Cash Provided by (Used in) Financing Activities 20.5M USD +761%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 59.9M shares +131%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 32.4M USD -21.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 35.4M USD +75.8%
Deferred Tax Assets, Gross 35.4M USD +75.9%
Depreciation 23K USD +360%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.3M USD -313%
Property, Plant and Equipment, Gross 25K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 20.3M USD +59.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.99M shares -0.14%
Additional Paid in Capital 172M USD +25.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 27K USD
Share-based Payment Arrangement, Expense 3.38M USD +9.92%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%